Favorable predictors for survival in advanced ALK‐positive non‐small cell lung cancer patients beyond crizotinib resistance

BACKGROUND: Crizotinib has demonstrated favorable efficacy in patients with advanced ALK‐positive non‐small cell lung cancer (NSCLC). Unfortunately, the majority of ALK‐positive patients ultimately develop acquired resistance within one year after the initiation of crizotinib treatment; however, the...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Haiyan, Yang, Guangjian, Yang, Lu, Yang, Yaning, Ma, Di, Li, Junling, Hao, Xuezhi, Xing, Puyuan, Wang, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons Australia, Ltd 2019
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500969/
https://www.ncbi.nlm.nih.gov/pubmed/30920172
http://dx.doi.org/10.1111/1759-7714.13050

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6500969/
https://www.ncbi.nlm.nih.gov/pubmed/30920172
http://dx.doi.org/10.1111/1759-7714.13050

Ejemplares similares